Eye Drop Candidate Targets Multiple Pathways in Diabetic Macular Edema
Key Points
- ITRI's small-molecule eye drop targets both ROCK and PKC pathways to inhibit abnormal vessel growth, reduce inflammation, and preserve retinal integrity in diabetic macular edema.
- Its delivery technology transports drug to the posterior segment, offering a non-invasive alternative to intravitreal injections, especially for anti-VEGF non-responders.
- The DME population is projected to approach 60 million by 2050, with the therapeutics market forecast to reach $13.29 billion by 2030.
A small-molecule eye drop in development at Industrial Technology Research Institute for diabetic macular edema (DME) is designed to address several disease mechanisms while offering a non-invasive alternative to treatments administered by intravitreal injection.
The investigational therapy simultaneously targets Rho-associated coiled-coil kinase (ROCK) and protein kinase C (PKC) signaling pathways through a novel mechanism of action. According to the development team, the dual-target approach is intended to inhibit abnormal blood vessel growth, reduce inflammation and help preserve retinal integrity.
The candidate also incorporates proprietary drug delivery technology designed to transport therapeutics to the posterior segment of the eye. Formulated as eye drops, the treatment could offer patients a less burdensome option than injections, which are commonly used to manage DME.
The approach may be particularly relevant for patients who do not respond adequately to anti-vascular endothelial growth factor (anti-VEGF) therapies. By avoiding repeated injections, the developers believe the treatment could improve adherence, reduce the burden on patients and healthcare systems, and limit risks associated with injection-based procedures.
The need for additional treatment options is underscored by the projected growth in DME prevalence. The global patient population is expected to approach 60 million by 2050, while the DME therapeutics market is forecast to reach $13.29 billion by 2030, representing a compound annual growth rate of 4.48%.
Beyond DME, the drug delivery platform could potentially be adapted for other diseases affecting the posterior segment of the eye, broadening its application across ophthalmology.
The candidate remains in development, and further clinical evidence will be needed to establish its safety and efficacy, including whether topical administration can deliver meaningful therapeutic concentrations to the retina.
For more information, visit www.itri.org.
Total Page Views: 7
